Literature DB >> 25980350

Optimization of dosing regimens and dosing in special populations.

F B Sime1, M S Roberts2, J A Roberts3.   

Abstract

Treatment of infectious diseases is becoming increasingly challenging with the emergence of less-susceptible organisms that are poorly responsive to existing antibiotic therapies, and the unpredictable pharmacokinetic alterations arising from complex pathophysiologic changes in some patient populations. In view of this fact, there has been a progressive work on novel dose optimization strategies to renew the utility of forgotten old antibiotics and to improve the efficacy of those currently in use. This review summarizes the different approaches of optimization of antibiotic dosing regimens and the special patient populations which may benefit most from these approaches. The existing methods are based on monitoring of antibiotic concentrations and/or use of clinical covariates. Measured concentrations can be correlated with predefined pharmacokinetic/pharmacodynamic targets to guide clinicians in predicting the necessary dose adjustment. Dosing nomograms are also available to relate observed concentrations or clinical covariates (e.g. creatinine clearance) with optimal dosing. More precise dose prediction based on observed covariates is possible through the application of population pharmacokinetic models. However, the most accurate estimation of individualized dosing requirements is achieved through Bayesian forecasting which utilizes both measured concentration and clinical covariates. Various software programs are emerging to ease clinical application. Whilst more studies are warranted to clarify the clinical outcomes associated with the different dose optimization approaches, severely ill patients in the course of marked infections and/or inflammation including those with sepsis, septic shock, severe trauma, burns injury, major surgery, febrile neutropenia, cystic fibrosis, organ dysfunction and obesity are those groups which may benefit most from individualized dosing.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotics; dose optimization; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring

Mesh:

Substances:

Year:  2015        PMID: 25980350     DOI: 10.1016/j.cmi.2015.05.002

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

Review 1.  Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.

Authors:  Vindana Chibabhai; Trusha Nana; Norma Bosman; Teena Thomas; Warren Lowman
Journal:  Infection       Date:  2017-09-15       Impact factor: 3.553

Review 2.  Rationalizing antimicrobial therapy in the ICU: a narrative review.

Authors:  Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier
Journal:  Intensive Care Med       Date:  2019-01-18       Impact factor: 17.440

3.  Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Authors:  Michael Neely; Michael Philippe; Teresa Rushing; Xiaowei Fu; Michael van Guilder; David Bayard; Alan Schumitzky; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Ther Drug Monit       Date:  2016-06       Impact factor: 3.681

4.  Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens.

Authors:  Zoe Oesterreicher; Iris Minichmayr; Robert Sauermann; Daniela Marhofer; Edith Lackner; Walter Jäger; Alexandra Maier-Salamon; Richard Schwameis; Charlotte Kloft; Markus Zeitlinger
Journal:  Eur J Clin Pharmacol       Date:  2017-09-17       Impact factor: 2.953

5.  Linguistic and cultural adaptation to the Portuguese language of antimicrobial dose adjustment software.

Authors:  Samuel Dutra da Silva; Geisa Cristina da Silva Alves; Farah Maria Drumond Chequer; Andras Farkas; Gergely Daróczi; Jason A Roberts; Cristina Sanches
Journal:  Einstein (Sao Paulo)       Date:  2020-01-27

Review 6.  Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice.

Authors:  Marios Spanakis; Athina E Patelarou; Evridiki Patelarou
Journal:  J Pers Med       Date:  2020-06-29

7.  Effects of ex vivo Extracorporeal Membrane Oxygenation Circuits on Sequestration of Antimicrobial Agents.

Authors:  Yuan Zhang; Hongbin Hu; Qing Zhang; Qing Ou; Huayou Zhou; Tong Sha; Zhenhua Zeng; Jie Wu; Jingrui Lu; Zhongqing Chen
Journal:  Front Med (Lausanne)       Date:  2021-12-01

8.  Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings.

Authors:  Iris K Minichmayr; Suzanne Kappetein; Margreke J E Brill; Lena E Friberg
Journal:  Antibiotics (Basel)       Date:  2022-08-01

9.  Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.

Authors:  Yaakov Dickstein; Leonard Leibovici; Dafna Yahav; Noa Eliakim-Raz; George L Daikos; Anna Skiada; Anastasia Antoniadou; Yehuda Carmeli; Amir Nutman; Inbar Levi; Amos Adler; Emanuele Durante-Mangoni; Roberto Andini; Giusi Cavezza; Johan W Mouton; Rixt A Wijma; Ursula Theuretzbacher; Lena E Friberg; Anders N Kristoffersson; Oren Zusman; Fidi Koppel; Yael Dishon Benattar; Sergey Altunin; Mical Paul
Journal:  BMJ Open       Date:  2016-04-20       Impact factor: 2.692

10.  Optimal control for colistin dosage selection.

Authors:  Aline Vidal Lacerda Gontijo; André V G Cavalieri
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-22       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.